Remote-controlled dexamethasone-duration on eye-surface with a micelle-magnetic nanoparticulate co-delivery system for dry eye disease

Bibliographic Details
Title: Remote-controlled dexamethasone-duration on eye-surface with a micelle-magnetic nanoparticulate co-delivery system for dry eye disease
Authors: Qinxiang Zheng, Chaoxiang Ge, Kexin Li, Longxin Wang, Xiaoyu Xia, Xiao Liu, Rashid Mehmood, Jianliang Shen, Kaihui Nan, Wei Chen, Sen Lin
Source: Acta Pharmaceutica Sinica B, Vol 14, Iss 8, Pp 3730-3745 (2024)
Publisher Information: Elsevier, 2024.
Publication Year: 2024
Collection: LCC:Therapeutics. Pharmacology
Subject Terms: Magnetic nanoparticle, Micelle, Dexamethasone, Eye drop, Bioavailability, Dry eye disease, Therapeutics. Pharmacology, RM1-950
More Details: Dexamethasone (DEX) is used to treat ocular surface diseases. However, regulating DEX duration in tears while preventing its absorption into the anterior chamber is critical for balancing its therapy effects and the side effects. In this study, a novel magnetic nanoparticle (MNP)-micelle (MC) co-delivery system (MMDS) was developed. The MC moiety in the MMDS served as the carrier for DEX and the MNP part endowed the MMDS with magnetic-responsive properties. To extend its residency, the MMDS was magnetically attracted by an external magnet after instilling, which acted as a precorneal drug-depot enabling a sustainable release of DEX in tears. With combination of magnet treatment, the topical instillation of MMDS@DEX significantly prolonged the DEX-retention in tears and increased the DEX-concentration in the cornea and conjunctiva, as well as concurrently reduced the DEX-level in the aqueous humor, when compared with the commercial DEX eye drop treatment. The combination of MMDS@DEX and magnet treatment exerted significantly better therapeutic effects against DED with smaller side effects than conventional treatments including DEX suspension, commercial DEX eye drops, as well as the MMDS@DEX treatment alone. The present work provided a new method for the effective delivery of DEX to ocular surface tissues while reducing its side effects, which will be beneficial to the treatments of a wide range of ocular surface diseases.
Document Type: article
File Description: electronic resource
Language: English
ISSN: 2211-3835
Relation: http://www.sciencedirect.com/science/article/pii/S2211383524001813; https://doaj.org/toc/2211-3835
DOI: 10.1016/j.apsb.2024.05.004
Access URL: https://doaj.org/article/c64013f78fff484181b57b284af097e9
Accession Number: edsdoj.64013f78fff484181b57b284af097e9
Database: Directory of Open Access Journals
More Details
ISSN:22113835
DOI:10.1016/j.apsb.2024.05.004
Published in:Acta Pharmaceutica Sinica B
Language:English